Evidence-based·Updated November 20, 2026·How we grade evidence

Ostarine (Enobosarm)

OtherSARM (research compound)

Ostarine (enobosarm) is a SARM that has been in company trials since 2006 and has never been approved. Phase 2 trials found gains of about 1 to 1.5 kg of lean body mass over 3 to 4 months in healthy older adults and in people with cancer-related weight loss, and some anti-tumor activity in advanced breast cancer. Two larger phase 3 trials in people starting chemotherapy for lung cancer (POWER 1 and 2, 651 participants) posted mixed responder results on ClinicalTrials.gov: more people kept their lean mass on ostarine than on placebo, but in one trial fewer people on ostarine than on placebo improved their stair-climb power. It lowers HDL cholesterol and, in men, testosterone. Case reports describe severe liver injury in people using products sold online, and FDA warns that SARMs are linked to liver injury, heart attack and stroke risk, infertility and other harms.

Taking Ostarine (Enobosarm) with other supplements or medications?Check your whole list for interactions. Free, no account.

Research compound: not an approved drug or dietary supplement

This compound is sold for research and is not FDA-approved for human use or as a dietary supplement. Human evidence is limited; purity and dosing of consumer products are unverified. The data below is an evidence review for education only. Talk to a clinician before considering it.

Quick decision guide

May help most

No approved or proven use; research participants in registered clinical trials only

Common dosing range

No approved or established dose. Company trials gave 0.1 to 3 mg by mouth once daily for muscle loss and 9 or 18 mg daily in advanced breast cancer, under medical monitoring

When to expect effects

Lean mass changes were measured after about 12 to 16 weeks in trials

Watch out for

Not FDA-approved; FDA says SARMs cannot be legally sold as dietary supplements and that "research use only" products are unapproved drugs; FDA links SARMs to liver injury and acute liver failure, heart attack and stroke risk, infertility, testicular shrinkage and psychosis; products sold online are often mislabeled; prohibited at all times in sport (WADA 2026 list, S1.2)

What is it

Ostarine (enobosarm, also coded MK-2866 and GTx-024) is an investigational drug that is not FDA-approved for any use, and FDA says products sold as SARMs cannot be legally marketed in the US as a dietary supplement or a drug. It is a nonsteroidal selective androgen receptor modulator (SARM): a lab-made compound that acts on the same receptor as testosterone. It was developed by the drug company GTx, Inc., which tested it from 2006 in trials for muscle loss in older adults and in people with cancer, for advanced breast cancer and for stress urinary incontinence in women; later trials are sponsored by Veru Inc. On ClinicalTrials.gov today, a phase 2 trial of enobosarm in people taking semaglutide for weight loss (NCT06282458, 168 participants) is listed as completed with no results posted, and a phase 2b trial (PLATEAU, NCT07446998) is active and not recruiting, with its primary completion estimated for October 2027. Products sold online as "Ostarine" or "MK-2866", including those labeled "research use only" or "not for human consumption", are not the trial drug: FDA calls them unapproved new drugs, and an independent lab analysis found many were mislabeled.

Is it worth it for you?

Use this as a quick fit check, not a diagnosis.

Worth considering if…

You qualify for a registered clinical trial of enobosarm on ClinicalTrials.gov and want to take part under medical supervision
You are worried about losing muscle with age, illness or weight-loss medicine and want to ask a doctor about approved treatments and proven measures such as resistance exercise and adequate protein

Probably skip if…

You would be buying "Ostarine", "MK-2866" or a "SARM" product online, including "research use only" liquids or capsules: FDA calls them unapproved drugs, and an analysis of 44 products sold as SARMs found that only 52% contained a SARM at all
You want to build muscle or improve sports performance: no published trial has tested whether ostarine improves strength or sports performance in healthy young people, and it is prohibited at all times under anti-doping rules
You have liver disease or have had jaundice: case reports describe severe cholestatic liver injury in people using ostarine products
You have heart disease, risk factors for heart attack or stroke, or low HDL cholesterol: ostarine lowered HDL in trials, and FDA warns SARMs may raise the risk of heart attack and stroke
You are pregnant, trying to conceive or breastfeeding, or you are a teenager: FDA lists infertility and pregnancy miscarriage among the problems linked to SARMs and warns specifically about use by teens and young adults

Evidence at a glance

lean body mass and stair climbing in healthy older adults

Limited Evidence
Effect
About 1.3 kg more lean mass than placebo at 3 mg daily over 12 weeks
Best fit
Research participants in controlled trials only
Time
12 weeks

muscle loss in people with cancer (cancer cachexia)

Limited Evidence
Effect
Median lean mass gain of 1.0 to 1.5 kg from baseline over about 16 weeks, against no change on placebo
Best fit
People with cancer-related weight loss taking part in controlled trials
Time
About 16 weeks (day 113)

advanced breast cancer that is androgen receptor positive

Limited Evidence
Effect
Clinical benefit at 24 weeks in about 3 in 10 women, with no comparison group
Best fit
Women with advanced androgen receptor-positive breast cancer enrolled in oncology trials
Time
Assessed at 16 to 24 weeks

Evidence for 3 uses

AI-assisted evidence assessment. Talk to your doctor before relying on any single supplement.

lean body mass and stair climbing in healthy older adults

Biomarker support
Limited Evidence

In a 12-week phase 2 trial run by the developer GTx, 120 healthy men over 60 and postmenopausal women were randomly assigned to placebo or ostarine 0.1, 0.3, 1 or 3 mg daily. At 3 mg, lean body mass measured by DXA rose by an average of 1.3 kg more than placebo (P < 0.001); the 1 mg dose gave 0.7 kg more than placebo, which was not statistically significant (P = 0.055). Fat mass fell by about 0.6 kg relative to placebo at 3 mg, and body weight did not change. Stair-climb power improved at 3 mg (P = 0.013 vs placebo). The same trial found a dose-dependent drop in HDL cholesterol (17% at 1 mg and 27% at 3 mg) and, in men, lower total testosterone and SHBG. The trial was small, short and company-run; it did not measure falls, fractures, disability or long-term safety.

Effect size
About 1.3 kg more lean mass than placebo at 3 mg daily over 12 weeks
Time to effect
12 weeks
Best fit
Research participants in controlled trials only
Less likely
Young, healthy or athletic people, who were not studied in this trial, and anyone using products sold online

Bottom line: One small company trial showed a modest gain in lean mass, with a drop in HDL cholesterol; it was never approved for this use.

muscle loss in people with cancer (cancer cachexia)

Biomarker support
Limited Evidence

In a phase 2 trial funded by GTx, 159 men over 45 and postmenopausal women with cancer and at least 2% weight loss in the previous 6 months received ostarine 1 mg, 3 mg or placebo daily for up to 113 days. In the 100 people with usable scans, median lean body mass rose 1.5 kg on 1 mg and 1.0 kg on 3 mg and did not change on placebo (0.02 kg). Stair-climb power also rose in both ostarine groups. These gains were compared with each group's own starting point, not tested against placebo. Serious adverse events, most often cancer progression, were similar across groups and none were judged related to the drug; 3 people on 3 mg had temporary rises in the liver enzyme ALT to 2 to 3 times normal. The company then ran two phase 3 trials of 3 mg daily for 147 days in people starting chemotherapy for non-small-cell lung cancer (POWER 1 and 2), with stair-climb power and lean body mass as co-primary endpoints analyzed as responder rates. Ostarine has not been approved for cancer-related muscle loss.

Effect size
Median lean mass gain of 1.0 to 1.5 kg from baseline over about 16 weeks, against no change on placebo
Time to effect
About 16 weeks (day 113)
Best fit
People with cancer-related weight loss taking part in controlled trials
Less likely
Healthy people seeking muscle gain, who were not studied

Bottom line: A phase 2 trial showed lean mass gains in people with cancer; larger phase 3 trials followed and the drug was not approved.

advanced breast cancer that is androgen receptor positive

Disease adjunct
Limited Evidence

In an open-label phase 2 trial funded by GTx at 35 centers in 9 countries, 136 postmenopausal women with previously treated ER-positive, HER2-negative advanced breast cancer were randomly assigned to ostarine 9 mg or 18 mg daily, with no placebo group. Among the 102 with confirmed androgen receptor-positive tumors, 32% (9 mg) and 29% (18 mg) had clinical benefit at 24 weeks. Serious (grade 3 or 4) drug-related side effects occurred in 8% (9 mg) and 16% (18 mg), most often raised liver enzymes (4% and 3%), high blood calcium (3% and 3%) and fatigue. In a separate small phase 2 trial in 16 evaluable patients with androgen receptor-positive metastatic triple-negative breast cancer, ostarine 18 mg daily plus pembrolizumab gave a clinical benefit rate of 25% at 16 weeks; that trial stopped early because the drug supply was withdrawn. Neither trial compared ostarine with standard treatment, and neither measured survival against a control group.

Effect size
Clinical benefit at 24 weeks in about 3 in 10 women, with no comparison group
Time to effect
Assessed at 16 to 24 weeks
Best fit
Women with advanced androgen receptor-positive breast cancer enrolled in oncology trials
Less likely
Anyone outside an oncology trial; this is cancer treatment research, not a muscle-building result

Bottom line: Uncontrolled trials showed some anti-tumor activity in advanced breast cancer; no approval followed.

How it works

Ostarine binds the androgen receptor, the receptor that testosterone acts on, and its developers designed it to act mainly on muscle and bone while sparing tissues such as the prostate and skin. In small trials it raised lean body mass by about 1 to 1.5 kg over 3 to 4 months. It also showed some of the same effects as other androgens: in the 12-week trial in older adults, men's total testosterone and sex hormone-binding globulin (SHBG) fell, and HDL ("good") cholesterol fell in a dose-dependent way across the men and women studied. In company-run phase 1 drug interaction studies, the antibiotic rifampin lowered ostarine levels in the blood (total exposure down 43%), and probenecid, a gout medicine, raised them (up 50%); itraconazole had no effect. Almost everything known about how ostarine behaves in the body comes from company-run trials of the pharmaceutical product at 0.1 to 18 mg a day, mostly lasting 3 months or less. How much ostarine, or what else, is in products sold online is unknown.

How to take it

1. Typical dose
There is no approved or established dose of ostarine, and no dose has been shown to be safe outside medical monitoring. In the published company trials, participants received 0.1, 0.3, 1 or 3 mg by mouth once daily for 12 weeks (healthy men over 60 and postmenopausal women), 1 or 3 mg once daily for up to 113 days (people with cancer and weight loss) and 9 or 18 mg once daily (postmenopausal women with advanced breast cancer). These are studied doses under trial monitoring, not recommendations.
2. Higher studied dose
The highest dose in published trials was 18 mg daily, given to women with advanced breast cancer: 16% of them had serious (grade 3 or 4) drug-related side effects, most often raised liver enzymes.
3. Timing
Not established outside trials, which gave it once daily.
4. With food
Not established.
5. Split dosing
Not established.
6. How long to try
Muscle trials lasted 12 weeks to about 5 months. There are no long-term human safety data.

What to track

If you have used it: tell your doctor and pharmacist, and ask whether liver tests, a lipid panel and hormone tests make sense
Yellowing of the skin or eyes, dark urine, pale stools or severe itching: signs of liver injury that need prompt medical care
Chest pain, shortness of breath, sudden weakness on one side or trouble speaking: get emergency care
Changes in mood, sleep, sexual function or testicle size

Bottom line: No dose is approved or established, and the products sold online were never tested in trials.

Safety

Know the common side effects, key cautions, and who should avoid it.

Common side effects

Headache and back pain were the most common adverse events in the 12-week trial in older adults, and overall adverse event rates were similar to placeboRises in the liver enzyme ALT, reported in 5 of 24 people (20.8%) on 3 mg daily and none on placebo in the same trialLower HDL cholesterol, and in men lower total testosterone and SHBG, in trialsRaised liver enzymes, high blood calcium and fatigue at 9 to 18 mg daily in women with advanced breast cancerIn an online survey of 343 self-reported SARM users (any SARM, products not tested), more than half reported side effects such as mood swings, smaller testicles and acne

Serious risks

Who should avoid it

Pregnancy & breastfeeding

There are no human data on ostarine in pregnancy or breastfeeding; the trials in women enrolled only postmenopausal women. FDA lists infertility and pregnancy miscarriage among the problems linked to SARMs. Avoid use if you are pregnant, breastfeeding or trying to conceive, and talk to your doctor.

Interactions

RifampinLow

In company-run phase 1 drug interaction studies, rifampin lowered ostarine levels in the blood (peak level down 23%, total exposure down 43%). The study authors judged the overall risk of clinically relevant drug interactions to be low. This was tested only with the pharmaceutical product.

ProbenecidLow

In company-run phase 1 drug interaction studies, probenecid raised blood levels of ostarine (total exposure up 50%) and of its main breakdown product (up 112%). The study authors judged the overall risk of clinically relevant drug interactions to be low. This was tested only with the pharmaceutical product.

Choosing a product

What to look for on the label, and what to be skeptical of.

Look for…

There is no FDA-approved ostarine or enobosarm product, so no label can show FDA approval
FDA says SARMs cannot be legally marketed in the US as a dietary supplement or a drug at this time, even when labeled as a supplement or "sold for research use only"
A label is no guide to contents: in an analysis of 44 products sold as SARMs, the amount matched the label in only 41%
The only legitimate way to receive enobosarm is a registered clinical trial listed on ClinicalTrials.gov

Be skeptical of…

"Clinically proven to build muscle": trials measured modest lean mass gains in older adults and people with cancer over 3 to 4 months, not muscle building in healthy people, and the drug was never approved
"Safer than steroids" or "no side effects": ostarine lowered HDL cholesterol and testosterone in trials, and FDA links SARMs to liver injury, heart attack and stroke risk and infertility
"Legal dietary supplement": FDA states SARMs cannot be legally marketed as dietary supplements
"For research use only" or "not for human consumption" products sold to consumers: FDA treats these as unapproved new drugs intended for human use
"FDA-approved" or "in phase 3, so it is safe": enobosarm is still investigational, and trial results apply to the tested pharmaceutical product only
"Undetectable" or "fine for tested athletes": ostarine is prohibited at all times on the WADA list and can be detected in doping tests

Frequently asked questions

Is ostarine FDA-approved?⌄

No. Ostarine (enobosarm) is not approved for any use. It remains an investigational drug: on ClinicalTrials.gov, a phase 2 trial in people taking semaglutide for weight loss is listed as completed with no results posted, and a phase 2b trial sponsored by Veru Inc. is active and not recruiting. FDA states that SARMs are not FDA approved.

Is it legal to buy ostarine as a supplement or a research chemical?⌄

FDA says SARMs cannot be legally marketed in the US as a dietary supplement or a drug at this time, and that products marketed as supplements or "sold for research use only" are considered unapproved drugs. FDA has sent warning letters to sellers of ostarine since at least 2017, including in December 2025, and says it has also pursued criminal actions against distributors.

What did the ostarine trials actually show?⌄

Company-run phase 2 trials found modest gains in lean body mass: about 1.3 kg more than placebo over 12 weeks at 3 mg daily in healthy older adults, and a median 1.0 to 1.5 kg over about 16 weeks in people with cancer-related weight loss. Two phase 3 trials in 651 people starting chemotherapy for lung cancer (POWER 1 and 2) posted results on ClinicalTrials.gov, not in a full published paper that we could find: lean mass was maintained in 41.9% on ostarine vs 30.4% on placebo in one trial and 46.5% vs 37.9% in the other, but stair-climb power improved by at least 10% in 29.4% vs 24.2% in one and in 19.5% vs 24.8% (fewer on ostarine) in the other. A phase 2 trial in 491 women with stress urinary incontinence posted similar responder numbers for ostarine and placebo (94 and 96 of 163 vs 87 of 165). No published trial has tested whether it improves strength or sports performance in young, healthy people.

Can ostarine damage the liver?⌄

Case reports describe serious liver injury with jaundice in people who used products sold as ostarine, including one young man who needed albumin dialysis and took about 6 months to recover. In company trials, raised liver enzymes were also seen, for example in 5 of 24 people on 3 mg daily in the 12-week trial in older adults. FDA lists liver injury and acute liver failure among the harms linked to SARMs. Anyone with yellow skin or eyes, dark urine or severe itching should get prompt medical care.

Is ostarine banned in sport?⌄

Yes. The 2026 WADA Prohibited List names enobosarm (ostarine) as a SARM under S1.2, other anabolic agents, which are prohibited at all times, in and out of competition. Athletes should check the current list with their anti-doping organization.

Can I take ostarine with my supplements or medicines?⌄

The only published interaction studies we found were company-run phase 1 studies of the pharmaceutical product: rifampin lowered ostarine levels by 43% and probenecid raised them by 50%, while itraconazole had no effect and ostarine did not change levels of celecoxib or rosuvastatin. No studies have tested it with supplements, and products sold online may contain other drugs. Ask a doctor or pharmacist to review your full list, and tell them if you have used ostarine.

References by claim

lean body mass and stair climbing in healthy older adults

Dalton et al., 2011 · PMC (2011) link

muscle loss in people with cancer (cancer cachexia)

Dobs et al., 2013 · PMC (2013) link

Crawford et al., 2016 · PMC (2016) link

advanced breast cancer that is androgen receptor positive

Palmieri et al., 2024 · PubMed (2024) link

Yuan et al., 2021 · PMC (2021) link

Safety

Bedi et al., 2021 · PMC (2021) link

Weinblatt et al., 2022 · PMC (2022) link

Mertens et al., 2024 · PubMed (2024) link

Koller et al., 2021 · PMC (2021) link

Cuba et al., 2026 · PubMed (2026) link

Adolf et al., 2026 · PubMed (2026) link

FDA Consumer Update: FDA Warns of Use of Selective Androgen Receptor Modulators (SARMs) Among Teens, Young Adults · FDA link

FDA warning letter to Panther Sports Nutrition (October 23, 2017): products labeled to contain ostarine and LGD-4033 · FDA link

Van Wagoner et al., 2017 · PMC (2017) link

Vignali et al., 2023 · PMC (2023) link

WADA Prohibited List (current list, S1.2 Other anabolic agents: SARMs, e.g. enobosarm (ostarine), LGD-4033 (ligandrol)) · World Anti-Doping Agency link

Interaction: Rifampin

Coss et al., 2016 · PubMed (2016) link

Track Ostarine (Enobosarm) with Pilora

Set up dose reminders, check interactions, and join the community in the Pilora app.

Evidence-based·Updated Nov 20, 2026·Evidence current as of Nov 20, 2026·How we grade evidence

Disclaimer: This compound is not approved by the FDA for human use and is not a dietary supplement. This page is an educational review of available research (much of it preclinical or early-stage), not a recommendation to use it. Consumer product quality is unregulated. Consult a qualified clinician.